These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10598685)

  • 1. Specific targeting immunotherapy of cancer with bispecific antibodies.
    Kudo T; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Kodama H; Ichiyama M; Takemura S; Yoshida H; Saeki H; Saijyo S; Takahashi J; Tominaga T; Matsuno S
    Tohoku J Exp Med; 1999 Aug; 188(4):275-88. PubMed ID: 10598685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
    Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
    Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
    Park JA; Cheung NV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
    Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma.
    Saijyo S; Kudo T; Katayose Y; Saeki H; Chiba N; Suzuki M; Tominaga T; Matsuno S
    Tohoku J Exp Med; 1996 Feb; 178(2):113-27. PubMed ID: 8727693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy.
    Ohta S; Tsukamoto H; Watanabe K; Makino K; Kuge S; Hanai N; Habu S; Nishimura T
    Immunol Lett; 1995 Jan; 44(1):35-40. PubMed ID: 7721341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
    Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
    Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.
    Gao Y; Xiong D; Yang M; Liu H; Peng H; Shao X; Xu Y; Xu C; Fan D; Qin L; Yang C; Zhu Z
    Leukemia; 2004 Mar; 18(3):513-20. PubMed ID: 14981526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
    Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.
    Bauer S; Renner C; Juwana JP; Held G; Ohnesorge S; Gerlach K; Pfreundschuh M
    Cancer Res; 1999 Apr; 59(8):1961-5. PubMed ID: 10213507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.